COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19.
COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19.
复制标题
DOI：
10.1093/abt/tbaa020
复制
发表时间：
2020-07-01
影响因子：
--
通讯作者：
Ho, Mitchell
中科院分区：
文献类型：
--
作者：
Yang, Lifei;Liu, Weihan;Ho, Mitchell
面对COVID-19的全球医疗危机，全球科学家正在合作开发针对该疾病的预防和治疗干预措施。抗体疗法为COVID-19的治疗带来了巨大的希望。2020年3月，中国抗体学会与抗体学会合作启动了“COVID-19抗体治疗追踪”（“追踪”）（https：//chineseantibody.org/covid-19-track/）项目，以追踪全球临床前和临床开发中基于抗体的COVID-19干预措施。这些数据是从公共领域收集的，并由志愿者持续进行验证。在此，我们根据截至2020年8月8日“追踪”中包含的150多个研发项目和分子的数据，展示探索性数据分析和可视化，以展示COVID-19抗体开发的最新趋势。我们主要按照数据的目标、格式、发展状况、开发者和来源国对数据进行分类。尽管在某些情况下细节有限，但所有抗SARS-CoV-2抗体候选物似乎都靶向病毒刺突蛋白（S蛋白），并且大多数是全长单克隆抗体。目前临床试验中的大多数COVID-19抗体治疗候选药物都是针对病毒特异性蛋白以外的靶点的再利用药物，而这些病毒特异性治疗抗体大多处于发现或临床前研究中。截至2020年8月8日，已有8种针对SARS-CoV-2S蛋白的候选抗体进入临床研究，包括LY-CoV 555、REGN-COV 2、JS 016、TY 027、CT-P59、BRII-196、BRII-198和SCTA 01。正在进行的SARS-CoV-2中和抗体的临床试验将有助于确定这些抗体作为治疗COVID-19和未来冠状病毒感染的新型疗法的效用。
Facing the COVID-19 global healthcare crisis, scientists worldwide are collaborating to develop prophylactic and therapeutic interventions against the disease. Antibody therapeutics hold enormous promise for the treatment of COVID-19. In March 2020, the Chinese Antibody Society, in collaboration with The Antibody Society, initiated the "COVID-19 Antibody Therapeutics Tracker" ("Tracker") (https://chineseantibody.org/covid-19-track/) program to track the antibody-based COVID-19 interventions in preclinical and clinical development globally. The data are collected from the public domain and verified by volunteers on an ongoing basis. Here, we present exploratory data analyses and visualization to demonstrate the latest trends of COVID-19 antibody development, based on data for over 150 research and development programs and molecules included in the "Tracker" as of 8 August 2020. We categorized the data mainly by their targets, formats, development status, developers and country of origin. Although details are limited in some cases, all of the anti-SARS-CoV-2 antibody candidates appear to target the viral spike protein (S protein), and most are full-length monoclonal antibodies. Most of the current COVID-19 antibody therapeutic candidates in clinical trials are repurposed drugs aimed at targets other than virus-specific proteins, while most of these virus-specific therapeutic antibodies are in discovery or preclinical studies. As of 8 August 2020, eight antibody candidates targeting the SARS-CoV-2S protein have entered clinical studies, including LY-CoV555, REGN-COV2, JS016, TY027, CT-P59, BRII-196, BRII-198 and SCTA01. Ongoing clinical trials of SARS-CoV-2 neutralizing antibodies will help define the utility of these antibodies as a new class of therapeutics for treating COVID-19 and future coronavirus infections.